Identification of Novel Mimotopes for the Development for the Development of Multivalent Breast Cancer Vaccines
Abstract
We planned to employ phage-display methodology to unveil novel breast cancer epitopes for the development of multivalent breast cancer vaccines. Some of the patients on our study were receiving Herceptin, a monoclonal antibody, that could complicate our analysis. We demonstrated that, in fact, our screening strategy would identify Herceptin. So, it was necessary to remove Herceptin from the sera before screening. We developed high affinity Herceptin mimotopes that could be employed to remove Herceptin from the serum samples, however we failed to successfully employ the Herceptin mimotope in a manner that would remove Herceptin from our test serum. Future studies will require samples from patients who were not receiving monoclonal antibody therapy. Over the same period, we successfully refined our algorithms to enable epitope definition based on results from polyclonal antiserum by using a collection of 5 monoclonal antibodies with defined specificity as a test case.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2007
- Accession Number
- ADA573369
Entities
People
- Jonathan Bramson
- Sukhbinder Dhesy-thind
Organizations
- McMaster University